PER® New York Lung Cancer Symposium | Conference

Examining New Approaches to Management of Immune-Related AEs in Lung Cancer

November 6th 2021

With the rise of immunotherapy, patients with lung cancer are experiencing improved outcomes that have allowed for prolonged survival, but it is important to ensure that the adverse effects associated with these novel agents are effectively managed so that their achieved efficacy does not come at the cost of quality of life.

Immunotherapy/Chemo Combos Remain Go-To Option in Growing Small Cell Lung Cancer Paradigm

November 6th 2021

Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.

Timing of Immunotherapy Stoppage in Lung Cancer Varies Depending on Progression, AEs, and Cure

November 6th 2021

Each situation for stopping immunotherapy in lung cancer has its own complex nuances to consider before the decision is made to cease treatment.

Dr. Brahmer on the Utility of Consolidative Immunotherapy Vs Targeted Therapy in NSCLC

November 6th 2021

Julie Renee Brahmer, MD, MSc, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell lung cancer.

Dr. Kris on Next Steps to Improve Outcomes in Lung Cancer

November 6th 2021

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the next steps to improve outcomes for patients with lung cancer.

Dr. Seetharamu on Utilizing a Patient-Centered Treatment Approach in Lung Cancer

November 5th 2021

Nagashree Seetharamu, MD, MBBS, discusses the importance of utilizing a patient-centered treatment approach in lung cancer.

Dr. Zauderer on Emerging Treatment Strategies in Mesothelioma

November 5th 2021

Marjorie G. Zauderer, MD, discusses emerging treatment strategies in mesothelioma.

Boost in Genomic Testing, Multidisciplinary Input Needed for Personalized Lung Cancer Care

November 5th 2021

Nagashree Seetharamu, MD, MBBS, discusses the importance of early and frequent genomic testing in patients with lung cancer, as well as remaining challenges faced in clinical practice and efforts being made to overcome them.

Research With Cellular Therapy Ramps Up in Mesothelioma

November 5th 2021

Marjorie G. Zauderer, MD, previews some of the new approaches in mesothelioma.

Clinical Trials Needed to Determine the Utility of Targeted Therapies in Oncogene-Driven Locally Advanced NSCLC

November 5th 2021

Julie Renee Brahmer, MD, MSc, discusses remaining questions regarding immunotherapy and targeted therapy in locally advanced NSCLC, data from the phase 3 PACIFIC and ADAURA trials, and her hopes for future clinical trials in the paradigm.

Chemoimmunotherapy Remains Best Choice for Some PD-L1–High Lung Cancers

November 10th 2020

November 10, 2020 - Nasser Hanna, MD, discusses immunotherapy and, although, it may be the right therapy for most patients with lung cancer expressing PD-L1 greater than or equal to 50%, for those who are at risk for cancer-related morbidity with early progressive disease, chemoimmunotherapy may be the more appropriate choice.

MET, RET, and TRK Inhibitors Achieve Standard-of-Care Status in Lung Cancer

November 9th 2020

Alterations in MET, RET, and NTRK have become established actionable drivers of oncogenesis in lung cancer, and therapeutics targeting these aberrations have since obtained regulatory approval from the FDA and have been incorporated into treatment guidelines.

KRAS G12C Emerges as an Actionable Alteration in NSCLC

November 9th 2020

Although historically considered to be undruggable, the KRAS G12C mutation has since emerged as an actionable alteration in the field of non–small cell lung cancer.

ctDNA Shows Promise as a Potential Biomarker for MRD in Locally Advanced NSCLC

November 9th 2020

Maximilian Diehn, MD, PhD, discusses how the use of circulating tumor DNA to analyze minimal residual disease status in patients with lung cancer and other solid tumors is a rapidly developing field with the potential to further personalize treatment decisions about adjuvant therapy.

Halmos Highlights Lessons Learned From the COVID-19 Crisis in Lung Cancer

November 9th 2020

The oncology community has risen up as a unified front in the battle against coronavirus disease 2019, launching pivotal research efforts to better understand the enemy and collecting data to develop effective therapeutics to fill the treatment arsenal.

TMB Shows Potential as Immunotherapy Biomarker in Lung Cancer, But Challenges Remain

November 7th 2020

Tumor mutational burden has been associated with response to immunotherapy in patients with lung cancer, but there have been various criticisms regarding the validity and routine use of this as a biomarker.

Management of Small Cell Lung Cancer Moves Forward With Immunotherapy

November 7th 2020

Frontline chemoimmunotherapy trials represent a critical milestone in extensive-stage small cell lung cancer, but one that requires better understanding of the methods that can be used to broaden the patient population in whom durable benefit is currently concentrated.

Efforts to Target Actionable Alterations in Lung Cancer Abound, Emphasizing Need for Testing

November 7th 2020

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.

Dr. Rohs on the Importance of Genetic Testing in NSCLC

November 7th 2020

Nicholas C. Rohs, MD, discusses the importance of genetic testing in non–small cell lung cancer.

Dr. Rizk on the Evolution of Surgery in Lung Cancer

November 7th 2020

Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.